Finding new osteoarthritis medicines via AI and genetics
The new drug is a starting point for therapies that treat OA at its source. Osteoarthritis (OA) is a chronic, painful joint disease and a leading cause of… read more.
The new drug is a starting point for therapies that treat OA at its source. Osteoarthritis (OA) is a chronic, painful joint disease and a leading cause of… read more.
Premarket evidence and regulatory characteristics offered little predictive value, researchers report in JAMA Health Forum More than one-third of high-risk therapeutic medical devices authorised for use in the… read more.
JCR Pharmaceuticals announced its development plan in Japan for givinostat, a treatment for Duchenne muscular dystrophy (DMD), following consultation with the Pharmaceuticals and Medical Devices Agency (PMDA). Based… read more.
Having high blood pressure is associated with greater intentions to follow doctors’ recommendations to take medication than people without high blood pressure but lesser intentions to make recommended… read more.
The first evidence that night work and chronic insomnia may increase the risk of developing long COVID comes from a new study led by ISGlobal, a centre supported by “la Caixa” Foundation,… read more.
The MHRA has approved Romvimza (vimseltinib ) to treat adult patients with tenosynovial giant cell tumour (TGCT) when it impacts movement or where surgery is not an option. TGCT (Giant cell… read more.
Royal Philips announced FDA 510(k) clearance of its next-generation reusable Philips SpO₂ clip sensor, reinforcing the company’s ongoing commitment to providing clinicians with trusted oxygen saturation measurements that… read more.
Having normal blood pressure, no diabetes and not smoking was associated with living nearly 13 years longer without dementia, according to a study published August 5, 2026, in Neurology® Open… read more.
Emily P. Hyle, MD, and Kenneth A. Freedberg, MD, of the Medical Practice Evaluation Center within the Department of Medicine at Mass General Brigham, are the lead and senior authors of a… read more.
Bristol Myers Squibb announced that the FDA has approved ZENBEXUS (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for the treatment of adult patients with multiple… read more.
Daiichi Sankyo and AstraZeneca announced that Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in China for the first-line treatment of adult patients with unresectable or… read more.
A multi-institutional study led by researchers at Children’s Hospital of Philadelphia (CHOP) found that telemedicine is becoming increasingly common for problem-based primary care, particularly for children with endocrine… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.